Loading...
Loading...
ESPR| Name | Value |
|---|---|
| Revenues | 73.8M |
| Cost of Revenue | 15.6M |
| Gross Profit | 58.2M |
| Operating Expense | 55.6M |
| Operating I/L | 2.6M |
| Other Income/Expense | -64.5M |
| Interest Income | 0.0M |
| Pretax | -61.9M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -61.9M |
Esperion Therapeutics, Inc. is a pharmaceutical company specializing in developing and commercializing medicines for patients with elevated low density lipoprotein cholesterol. Their lead product candidates, NEXLETOL and NEXLIZET tablets, target the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company generates revenue through the sales of these medications, which are designed to address the needs of individuals with specific cholesterol-related conditions.
